2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis) to treat adults with ...